In summary, our findings reveal that cPKM enhances ICC growth, metastasis, and resistance to paclitaxel by promoting STMN1 and TGFB1 expression and by causing abnormal activation of HSCs, exacerbating fibrosis, and ultimately leading to vascular collapse. The gene discussed is TGFB1; the disease is intrahepatic cholangiocarcinoma.